JP2022546055A5 - - Google Patents
Info
- Publication number
- JP2022546055A5 JP2022546055A5 JP2022513256A JP2022513256A JP2022546055A5 JP 2022546055 A5 JP2022546055 A5 JP 2022546055A5 JP 2022513256 A JP2022513256 A JP 2022513256A JP 2022513256 A JP2022513256 A JP 2022513256A JP 2022546055 A5 JP2022546055 A5 JP 2022546055A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl group
- formula
- alkyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910820620 | 2019-08-29 | ||
| CN201910820597 | 2019-08-29 | ||
| CN201910820597.7 | 2019-08-29 | ||
| CN201910820620.2 | 2019-08-29 | ||
| PCT/CN2020/112105 WO2021037205A1 (zh) | 2019-08-29 | 2020-08-28 | 化合物和药物缀合物及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022546055A JP2022546055A (ja) | 2022-11-02 |
| JP2022546055A5 true JP2022546055A5 (enExample) | 2023-09-05 |
Family
ID=74684158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513256A Ceased JP2022546055A (ja) | 2019-08-29 | 2020-08-28 | 化合物、薬物複合体及びその調製方法と使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230076803A1 (enExample) |
| EP (1) | EP4023659A4 (enExample) |
| JP (1) | JP2022546055A (enExample) |
| CN (1) | CN113891892B (enExample) |
| TW (1) | TW202122093A (enExample) |
| WO (1) | WO2021037205A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118291456A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105414A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| JP7507495B2 (ja) | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN113227376B (zh) | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7610848B2 (ja) | 2019-05-22 | 2025-01-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| CN113286888B (zh) | 2019-05-22 | 2023-12-22 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| EP4396193A4 (en) | 2021-08-30 | 2025-07-02 | Hongene Biotech Corp | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGUES |
| CN118401539A (zh) | 2021-12-15 | 2024-07-26 | 兆维生物科技公司 | 官能化的n-乙酰半乳糖胺类似物 |
| TWI866590B (zh) * | 2022-11-08 | 2024-12-11 | 大陸商南京明德新藥研發有限公司 | 含七元雜環的四價綴合基團及其應用 |
| US12116382B2 (en) | 2022-11-28 | 2024-10-15 | Hongene Biotech Corporation | Functionalized N-acetylgalactosamine analogs |
| EP4683666A1 (en) * | 2023-03-23 | 2026-01-28 | ModernaTX, Inc. | Peg targeting compounds for delivery of therapeutics |
| EP4755898A1 (en) * | 2023-08-02 | 2026-06-10 | Nitto Denko Corporation | Method for producing oligonucleotide |
| CN119799706B (zh) * | 2024-07-08 | 2026-03-06 | 杭州天龙药业有限公司 | 靶向调控HBV基因表达的siRNA及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2229186A2 (en) | 2007-12-04 | 2010-09-22 | Alnylam Pharmaceuticals Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| WO2010012244A1 (zh) * | 2008-08-01 | 2010-02-04 | 苏州瑞博生物技术有限公司 | 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用 |
| WO2011154331A1 (en) * | 2010-06-10 | 2011-12-15 | F. Hoffmann-La Roche Ag | Polymers for delivery of nucleic acids |
| US10155780B2 (en) * | 2012-10-29 | 2018-12-18 | Molecular Transfer, Inc. | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| WO2015006740A2 (en) | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| EP3027222A1 (en) * | 2013-07-31 | 2016-06-08 | QBI Enterprises Ltd. | Sphingolipid-polyalkylamine-oligonucleotide compounds |
| CN107109405A (zh) * | 2014-06-06 | 2017-08-29 | 索尔斯蒂斯生物有限公司 | 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 |
| EP3315608B1 (en) * | 2015-06-26 | 2020-09-16 | Suzhou Ribo Life Science Co., Ltd. | Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof |
| CN111164091B (zh) * | 2017-06-02 | 2025-01-07 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| CA3065523A1 (en) * | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11603532B2 (en) * | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| CN110959011B (zh) * | 2017-12-29 | 2023-03-28 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
-
2020
- 2020-08-28 JP JP2022513256A patent/JP2022546055A/ja not_active Ceased
- 2020-08-28 WO PCT/CN2020/112105 patent/WO2021037205A1/zh not_active Ceased
- 2020-08-28 EP EP20856439.3A patent/EP4023659A4/en not_active Withdrawn
- 2020-08-28 CN CN202080032571.7A patent/CN113891892B/zh active Active
- 2020-08-28 TW TW109129461A patent/TW202122093A/zh unknown
- 2020-08-28 US US17/639,063 patent/US20230076803A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Uehara et al. | Targeted delivery to macrophages and dendritic cells by chemically modified mannose ligand-conjugated siRNA | |
| Biscans et al. | Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo | |
| McClorey et al. | An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies | |
| Heemskerk et al. | In vivo comparison of 2′‐O‐methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping | |
| AU2017200365C1 (en) | Compositions and methods for modulating apolipoprotein c-iii expression | |
| JP2022501059A5 (enExample) | ||
| Godeau et al. | Lipid-conjugated oligonucleotides via “click chemistry” efficiently inhibit hepatitis C virus translation | |
| JP2021503940A5 (enExample) | ||
| CA2663601C (en) | Duplex oligonucleotide complexes and methods for gene silencing by rna interference | |
| US20250312422A1 (en) | Compositions and methods for facilitating delivery of synthetic nucleic acids to cells | |
| HRP20250408T1 (hr) | Kojugati i njihova priprema i uporaba | |
| JP2022533841A5 (enExample) | ||
| Sharma et al. | Novel cluster and monomer-based GalNAc structures induce effective uptake of siRNAs in vitro and in vivo | |
| BR112016022855B1 (pt) | Compostos e composições para modular a expressão de pkk e seus usos | |
| Kiviniemi et al. | Utilization of intrachain 4′-C-azidomethylthymidine for preparation of oligodeoxyribonucleotide conjugates by click chemistry in solution and on a solid support | |
| JP2022535708A5 (enExample) | ||
| JP2021533800A5 (enExample) | ||
| JP2025038097A (ja) | 核酸、薬物組成物及び複合体ならびに調製方法と使用 | |
| US20200108089A1 (en) | Gemcitabine Derivatives for Cancer Therapy | |
| Ren et al. | Non-coding RNAs in heart failure: epigenetic regulatory mechanisms and therapeutic potential | |
| EP2125029B1 (en) | Construction and use of transfection enhancer elements | |
| Wang | Poly (ethylene) Glycol-Based Bottlebrush Polymers as Nanocarriers for Oligonucleotide Therapeutics: Design, Synthesis, and Applications | |
| WO2024255748A1 (zh) | 靶向17-β-羟基类固醇脱氢酶13的核酸及其用途 | |
| JP2025514180A5 (enExample) | ||
| WO2024260379A1 (zh) | 靶向已酮糖激酶的核酸及其用途 |